AR074966A1 - Compuestos amino-heterociclicos - Google Patents
Compuestos amino-heterociclicosInfo
- Publication number
- AR074966A1 AR074966A1 ARP100100153A ARP100100153A AR074966A1 AR 074966 A1 AR074966 A1 AR 074966A1 AR P100100153 A ARP100100153 A AR P100100153A AR P100100153 A ARP100100153 A AR P100100153A AR 074966 A1 AR074966 A1 AR 074966A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- group
- haloalkyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente proporciona compuestos inhibidores de PDE9 de fórmula (1). También se proporcionan composiciones farmacéuticas que contienen los compuestos de fórmula (1), y usos de los mismos en el tratamiento de trastornos neurodegenerativos y cognitivos, tales como la enfermedad de Alzheimer y esquizofrenia. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que R1 se selecciona entre el grupo constituido por (i) hidrógeno, (ii) alquilo C1-4, (iii) alquenilo C2-4, (iv) alquinilo C2-4, (v) alcoxi C1-4, (vi) haloalquilo C1-4, (vii) cicloalquilo C3-6, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4, ciano, carboxi y carbamoilo, (viii) heterocicloalquilo de 4 a 10 miembros, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4, ciano, carboxi y carbamoilo, (ix) arilo, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4, ciano, carboxi y carbamoilo, y (x) heteroarilo, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4, ciano, carboxi y carbamoilo; R2 se selecciona entre el grupo constituido por hidrógeno, alquilo C1-4, haloalquilo C1-4, ciano y cicloalquilo C3-6; R3 se selecciona entre el grupo constituido por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, heterocicloalquilo, arilo y heteroarilo. cada uno de los cuales puede estar opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo y haloalquilo C1-4; n es 1 ó 2; A es -CR4R5- o-CHRa-CHRb-; R4 se selecciona entre el grupo constituido por (i) hidrógeno, (ii) alquilo C1-7, (iii) cicloalquilo C3-8, (iv) heterocicloalquilo de 4 a 10 miembros, (v) arilo, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4, cicloalquilo C3-6, ciano, carboxi y carbamoilo, (vi) heteroarilo, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4, cicloalquilo C3-6, ciano, carboxi y carbamoilo, y (vii) LR6, donde L se selecciona entre el grupo constituido por -CH2-, -NR7- y -O-; R6 es arilo, heteroarilo, alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo de 4 a 10 miembros o alcoxi C1-8, cada uno de los cuales puede estar opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4. cicloalquilo C3-6, ciano, carboxi y carbamoilo; y R7 es hidrógeno, metilo o etilo; R5 se selecciona entre el grupo constituido por hidrógeno, hidroxilo, alcoxi C1-4, halógeno y alquilo C1-6; o R4 y R5, junto con el carbono al que están unidos, forman un anillo cicloalquilo o heterocicloalquilo que incorpora opcionalmente un grupo oxo y está opcionalmente sustituido con alquilo C1-8, cicloalquilo C3-8, halo, alcoxi C1-8 o haloalquilo C1-3; Ra es alcoxi C1-4 o R8-O-C(O)-, donde R8 es alquilo C1-4; y Rb es arilo, heteroarilo o heterocicloalquilo, opcionalmente sustituido con halo, alquilo C1-8, cicloalquilo C3-8, alcoxi C1-8 o haloalquilo C1-3; o Ra y Rb junto con los carbonos a los que están unidos, forman un anillo cicloalquilo o heterocicloalquilo que incorpora opcionalmente un grupo oxo y está opcionalmente sustituido con alquilo C1-8, cicloalquilo C3-8, halo, alcoxi C1-8 o haloalquilo C1-3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20609209P | 2009-01-26 | 2009-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074966A1 true AR074966A1 (es) | 2011-02-23 |
Family
ID=42062324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100153A AR074966A1 (es) | 2009-01-26 | 2010-01-25 | Compuestos amino-heterociclicos |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8278295B2 (es) |
| EP (1) | EP2389382B1 (es) |
| JP (1) | JP5656874B2 (es) |
| KR (1) | KR101417237B1 (es) |
| CN (1) | CN102292340B (es) |
| AR (1) | AR074966A1 (es) |
| AU (1) | AU2010207507B2 (es) |
| CA (1) | CA2748864C (es) |
| DK (1) | DK2389382T3 (es) |
| ES (1) | ES2420860T3 (es) |
| HK (1) | HK1163092A1 (es) |
| HR (1) | HRP20130530T1 (es) |
| IL (2) | IL213923A (es) |
| MX (1) | MX2011007862A (es) |
| PL (1) | PL2389382T3 (es) |
| PT (1) | PT2389382E (es) |
| SG (1) | SG172805A1 (es) |
| SI (1) | SI2389382T1 (es) |
| TW (1) | TWI404721B (es) |
| UY (1) | UY32391A (es) |
| WO (1) | WO2010084438A1 (es) |
| ZA (1) | ZA201105931B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| EP3357495B1 (en) | 2008-11-19 | 2019-12-25 | Axovant Sciences GmbH | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| BRPI1014793A2 (pt) * | 2009-05-11 | 2016-04-05 | Envivo Pharmaceuticals Inc | tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase |
| CA2989633A1 (en) | 2010-05-17 | 2011-11-24 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| CA2810696C (en) | 2010-09-07 | 2018-09-18 | Astellas Pharma Inc. | Pyrazoloquinoline compound |
| TW201300390A (zh) | 2010-09-07 | 2013-01-01 | Astellas Pharma Inc | 喹□啉化合物 |
| EP3121178B1 (en) | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
| US9434733B2 (en) | 2012-01-26 | 2016-09-06 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
| KR20140138694A (ko) | 2012-02-03 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도 |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| CN102786525B (zh) * | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EP2908827A4 (en) * | 2012-10-19 | 2016-08-31 | Celus Pharmaceuticals Inc | VITAMIN D ANALOGUE FOR THE TREATMENT OF A NEUROLOGICAL DISEASE |
| CN103207246B (zh) * | 2012-12-21 | 2017-10-10 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法 |
| CA3193201A1 (en) * | 2014-05-06 | 2015-11-12 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| JP6539724B2 (ja) * | 2014-08-27 | 2019-07-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｔａａｒリガンドとしての置換アゼチジン誘導体 |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| FI3865484T3 (fi) | 2015-07-07 | 2024-01-24 | H Lundbeck As | Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon |
| WO2017019724A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
| US10370337B2 (en) | 2015-07-29 | 2019-08-06 | Merck, Sharp & Dohme Corp. | Oxy-cyanoquinolinone PDE9 inhibitors |
| US10376504B2 (en) | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| EP3349853B1 (en) | 2015-09-15 | 2023-12-20 | Praxis Bioresearch, LLC | Prodrugs of fencamfamine |
| CN105467028A (zh) * | 2015-11-18 | 2016-04-06 | 北京万全德众医药生物技术有限公司 | 气相色谱法分离测定鲁拉西酮中间体光学异构体的方法 |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| MX2018016127A (es) | 2016-07-06 | 2019-05-30 | Imara Inc | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. |
| US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
| KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| BR112018013247A2 (pt) | 2016-10-28 | 2018-12-04 | H Lundbeck As | tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos |
| PT3541784T (pt) | 2016-11-18 | 2023-11-22 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
| CA3047408A1 (en) | 2016-12-28 | 2018-07-05 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
| CA3051976A1 (en) * | 2017-02-23 | 2018-08-30 | Boehringer Ingelheim International Gmbh | New medical use of compound iii |
| CN106957300A (zh) * | 2017-04-12 | 2017-07-18 | 苏州汉德创宏生化科技有限公司 | 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法 |
| RU2758373C2 (ru) * | 2017-05-22 | 2021-10-28 | Топадур Фарма Аг | Новые активаторы растворимой гуанилатциклазы и ингибиторы фосфодиэстеразы с двойным механизмом действия и их применение |
| IL270792B2 (en) | 2017-05-26 | 2024-01-01 | Imara Inc | Methods for the preparation and use of PDE9 inhibitors |
| AU2018276566A1 (en) | 2017-06-01 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising PDE9 inhibitor |
| SG10202113198TA (en) | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| KR102627790B1 (ko) | 2017-06-01 | 2024-01-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제 |
| US11311530B2 (en) | 2017-06-01 | 2022-04-26 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| RU2019144010A (ru) | 2017-06-08 | 2021-07-13 | Мерк Шарп И Доум Корп. | Пиразолопиримидиновые ингибиторы pde9 |
| CN111655695A (zh) | 2017-11-27 | 2020-09-11 | 达特神经科学有限公司 | 作为pde1抑制剂的取代的呋喃并嘧啶化合物 |
| HRP20240363T1 (hr) | 2018-05-25 | 2024-06-07 | Cardurion Pharmaceuticals, Inc. | Monohidratni i kristalni oblici 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a] pirazin-8-ona |
| AU2020235187B8 (en) * | 2019-03-08 | 2024-02-08 | Transthera Sciences (Nanjing), Inc. | Uses of phosphodiesterase inhibitors |
| AU2020322465A1 (en) * | 2019-07-29 | 2022-02-24 | Constellation Pharmaceuticals, Inc. | Compounds for use in treating neurological disorders |
| WO2024107445A1 (en) * | 2022-11-15 | 2024-05-23 | Freedom Biosciences, Inc. | Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法 |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| SE0103795D0 (sv) | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Compounds and method for the treatment of överactive bladder |
| KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
| US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| AU2002363960B2 (en) * | 2001-12-06 | 2008-07-10 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| NZ580904A (en) * | 2007-05-11 | 2012-02-24 | Pfizer | Amino-heterocyclic compounds for inhibiting pde9 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
-
2009
- 2009-12-31 TW TW098146481A patent/TWI404721B/zh not_active IP Right Cessation
-
2010
- 2010-01-13 PL PL10701921T patent/PL2389382T3/pl unknown
- 2010-01-13 JP JP2011547011A patent/JP5656874B2/ja not_active Expired - Fee Related
- 2010-01-13 PT PT107019218T patent/PT2389382E/pt unknown
- 2010-01-13 CN CN201080005394.XA patent/CN102292340B/zh not_active Expired - Fee Related
- 2010-01-13 ES ES10701921T patent/ES2420860T3/es active Active
- 2010-01-13 SG SG2011047594A patent/SG172805A1/en unknown
- 2010-01-13 KR KR1020117019758A patent/KR101417237B1/ko not_active IP Right Cessation
- 2010-01-13 DK DK10701921.8T patent/DK2389382T3/da active
- 2010-01-13 SI SI201030250T patent/SI2389382T1/sl unknown
- 2010-01-13 WO PCT/IB2010/050133 patent/WO2010084438A1/en active Application Filing
- 2010-01-13 MX MX2011007862A patent/MX2011007862A/es active IP Right Grant
- 2010-01-13 AU AU2010207507A patent/AU2010207507B2/en not_active Ceased
- 2010-01-13 EP EP10701921.8A patent/EP2389382B1/en not_active Not-in-force
- 2010-01-13 CA CA2748864A patent/CA2748864C/en not_active Expired - Fee Related
- 2010-01-25 UY UY0001032391A patent/UY32391A/es not_active Application Discontinuation
- 2010-01-25 AR ARP100100153A patent/AR074966A1/es unknown
- 2010-01-26 US US12/693,480 patent/US8278295B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 IL IL213923A patent/IL213923A/en not_active IP Right Cessation
- 2011-08-12 ZA ZA2011/05931A patent/ZA201105931B/en unknown
-
2012
- 2012-04-18 HK HK12103808.2A patent/HK1163092A1/xx not_active IP Right Cessation
- 2012-08-31 US US13/600,522 patent/US8618117B2/en not_active Expired - Fee Related
-
2013
- 2013-06-12 HR HRP20130530AT patent/HRP20130530T1/hr unknown
- 2013-11-27 US US14/091,404 patent/US20140088081A1/en not_active Abandoned
-
2016
- 2016-07-21 IL IL246882A patent/IL246882A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
| AR066502A1 (es) | Compuestos amino- heterociclicos | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
| AR071857A1 (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| AR076236A1 (es) | Compuestos organicos y sus usos | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
| CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR070535A1 (es) | Compuestos inhibidores de raf y metodos para usarlos | |
| AR074341A1 (es) | Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer. | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR075517A1 (es) | Derivados de isoxazol-isoxazol y de isoxazol-isotiazol | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
| AR076235A1 (es) | Compuestos organicos y sus usos | |
| AR084515A1 (es) | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |